Investor Relations

Tear Sheet

Company Profile

BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. Our wholly owned subsidiary, OnkosXcel Therapeutics, is focused on the development of medicines in immuno-oncology. The Company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indications. 

Corporate/Investors

BioXcel Therapeutics
Erik Kopp
T: 203-494-7062
Ekopp@bioxceltherapeutics.com

Investors

Russo Partners
Nick Johnson
T: 303-482-6405
Nic.Johnson@russopartnersllc.com

Media

Transfer Agent

American Stock Transfer and Trust

Auditor

Ernst & Young LLP

Legal Counsel

Latham & Watkins LLP

Stock Quote

Minimum 15 minutes delayed. Source: LSEG

Stock Chart

SEC Filings

Filing date Form Description Filing Group
EFFECT

EFFECT

Other
8-K

Report of unscheduled material events or corporate event

Current Reports
4

Statement of changes in beneficial ownership of securities

3,4,5
3

Initial filing by director officer or owner of more than ten percent

3,4,5
S-3

Simplified registration form

Registration Statements

Minimum 15 minutes delayed. Source: LSEG